Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Consensus Rating of “Moderate Buy” by Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.00.

A number of research analysts have commented on the company. Wall Street Zen cut Tenaya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenaya Therapeutics in a research note on Thursday, July 2nd.

Tenaya Therapeutics Stock Performance

TNYA stock opened at $0.77 on Friday. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35. The firm’s 50 day moving average price is $0.78 and its 200-day moving average price is $0.76. The firm has a market cap of $167.76 million, a PE ratio of -1.64 and a beta of 2.83.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $7.50 million. Equities research analysts predict that Tenaya Therapeutics will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Comerica Bank purchased a new position in shares of Tenaya Therapeutics during the first quarter worth about $50,000. AQR Capital Management LLC purchased a new position in shares of Tenaya Therapeutics in the 1st quarter valued at approximately $442,000. Woodline Partners LP increased its stake in Tenaya Therapeutics by 30,563.2% in the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company’s stock valued at $3,373,000 after buying an additional 5,896,873 shares during the period. Marshall Wace LLP acquired a new position in shares of Tenaya Therapeutics during the second quarter worth about $90,000. Finally, Cerity Partners LLC grew its holdings in Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company’s stock worth $67,000 after acquiring an additional 88,424 shares during the period. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno?associated virus (AAV) platform, the company aims to deliver durable, one?time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.